April 9, 2013, Charlottetown: Neurodyn Inc. announced today that the company’s wholly owned contract research subsidiary CNS|CRO. has expanded its marketing efforts in response to inquiries from the pharmaceutical industry.
The marketing effort includes an expanded website at www.cnscro.com,the addition of a full time marketing position for the company, and negotiations with several pharmaceutical companies who are interested in either contracting CNS|CRO services or licensing the company’s proprietary models.
CNS|CRO holds patent rights to proprietary models of ALS and Parkinson’s disease complex, and other neurological disease conditions. These models are the only slowly progressing, environmentally based models for these conditions in the world, and they closely reflect the progression of these diseases in humans.
“We are receiving an increasing number of inquiries from the pharmaceutical industry about the value of our models, and we recognize the commercial opportunity for an expansion of our business activity,” said Dr.Denis Kay, Director of Operations for CNS|CRO.
CNS|CRO partners closely with several key medical researchers at the Atlantic Veterinary College at the University of Prince Edward Island, and utilizes the institution’s state of the art facilities for a portion of the contract research. The combined expertise makes CNS|CRO a leader in pre‐clinical contract research for neurological diseases.
CSN|CRO’s parent company Neurodyn Inc. (www.neurodyn.ca) is a Canadian biotechnology company using a portfolio approach to identifying, validating and developing natural bioactives into both prescription drugs and natural products for the early stage treatment of neurological diseases.
Based in Charlottetown, Prince Edward Island, the company has developed its BioActives Discovery Engine™ through a combination of 1) international partners with demonstrated historical knowledge of natural compounds, 2) in‐house medicinal chemistry capability, and 3) proprietary pre‐clinical models of neurological disease. Neurodyn is using this powerful engine
for its Rx and natural product development programs to out‐license or sell validated drug candidatesto pharmaceutical and consumer health players.
Neurodyn’s lead technologies include NeuroPro™, for use in early stage Parkinson’s disease which will begin sales in Canada in early 2013, Progranulin (ND602), a novel therapeutic demonstrating pre‐clinical efficacy in ALS, Parkinson’s disease, Alzheimer’s disease and Spinal Muscular Atrophy, and a Nerve Pain Treatment (NQ1123), which is being developed as a prescription drug for a topical nerve pain condition.
Formore information, contact:
Dr.Denis Kay 902‐314 0776 (mobile) dgkay@neurodyn.ca
Mr. Kenneth Cawkell 604‐619‐0990 (mobile) kcawkell@neurodyn.ca
Mr. Robert Cervelli 902‐222‐4391 (mobile) cervelli@neurodyn.ca
Neurodyn Inc., Suite 508,NRC‐INH, 550University Avenue, Charlottetown PE C1A 4P3